Printer Friendly

Deal snapshot: AMGEN TO REACQUIRE PRODUCT RIGHTS THREE PRODUCTS FROM GSK.

MANews-(C)2009-2015

US-based biotechnology company Amgen (NASDAQ: AMGN) has entered into a definitive agreement with UK-based drugmaker GSK to reacquire all of its remaining rights to Prolia (denosumab), Xgeva (denosumab) and Vectibix (panitumumab) in 48 countries in Asia, South America, Europe, Australia and other regions throughout the world, the company said.

The agreement involves key expansion markets for Amgen including Brazil, China, Colombia, Hong Kong, Israel, Singapore, South Korea, Taiwan and Thailand. GSK has held select regional rights to Prolia and Xgeva since 2009 and to Vectibix since 2010 under license from Amgen.

Country: UK

Sector: Pharmaceuticals

Target: rights to Prolia (denosumab), Xgeva (denosumab) and Vectibix (panitumumab) in 48 countries

Buyer: Amgen

Vendor: GSK

Deal size in USD:

Type: Corporate Acquisition

Financing:

Status: Agreed

Buyer advisor: , ,

Comment: Amgen buys back rights to three drugs/in 48 countries

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M & A Navigator
Date:Dec 16, 2015
Words:138
Previous Article:Deal snapshot: ARBOR INVESTMENTS ACQUIRES DPI SPECIALTY FOODS.
Next Article:Deal snapshot: VISTRA GROUP BUYS MALTA YACHT SERVICE PROVIDER.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters